AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Quanterix Announces $50,000 in Grants to Support Promising Oncology Research

May 16, 2019

LEXINGTON, Mass.--(BUSINESS WIRE)--May 16, 2019--

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a call for proposals for a new Accelerator Grant Program. Designed to help facilitate breakthroughs in science and medicine, this year’s Accelerator Grant Program will award up to $50,000 toward the cost of research in Quanterix’ Accelerator Lab to help advance the most exciting biomarker research using Quanterix’ ultrasensitive Simoa technology.

“Our Simoa technology powers groundbreaking research that can disrupt the way diseases are diagnosed and treated, and we want to make sure that technology remains within reach for the most promising discoveries,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix. “Our rapid growth has allowed us to expand the capabilities of our in-house pharmaceutical services lab, and the Accelerator Grant Program extends the reach of these resources, giving more researchers the opportunity to leverage the science of Simoa for their projects with the goal of improving today’s healthcare system.”

This year, special consideration will be given to proposals leveraging the Simoa CorPlex 10 Plex planar array or other Simoa planar arrays, which enable the accuracy, sensitivity and reproducibility needed to address many of today’s unmet needs in oncology, immuno-oncology and other research areas. Specifically, proposals focused on tumor-shrinking markers, hot and cold tumor differentiation, cytokine release syndrome, cytokine release neurotoxicity, CAR T-cell therapies, patient stratification, predictive biomarkers, and liquid biopsies will be given special attention as they address some of the greatest unmet needs in research today.

“Biomarker research continues to provide a treasure trove of information powering medical breakthroughs and we are optimistic that together we’ll be able to drive change,” continued Hrusovsky. “We feel there is a lot of untapped potential in this area that could help us take down the most lethal diseases, including cancer. That’s why we’re seeking applicants with a focus across these specific areas in which biomarkers have already shown significant promise.”

Quanterix’ state-of-the-art Accelerator Lab is a dedicated CLIA-certified laboratory environment for custom assay development and clinical sample testing. Staffed with a large team of scientists dedicated exclusively to Accelerator projects to which grant recipients will also have access, the Lab offers some of the greatest ultra-sensitive assay development and instrument operation experiences available. Since its launch in 2014, the Lab has powered considerable advancements in disease detection and drug development, helping researchers obtain quick, robust data that would otherwise take more time and added resources.

To be considered for the grant, all interested parties must submit their proposals by June 30, 2019. Recipients will be notified by July 31, 2019.

To submit your proposal and learn more about the Accelerator Grant Program, click here.

About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit  https://www.quanterix.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190516005710/en/

CONTACT: PAN Communications

Lindsay Poole, 617-502-4300

quanterix@pancomm.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE

SOURCE: Quanterix Corporation

Copyright Business Wire 2019.

PUB: 05/16/2019 10:30 AM/DISC: 05/16/2019 10:31 AM

http://www.businesswire.com/news/home/20190516005710/en